ArticleBMC global and public health2024
The impact of the exodus of big pharmaceutical companies from Nigeria on antimicrobial resistance in the West African subregion.
Article in BMC global and public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- From classrooms to practice: does pre-service training for one health professions provide readiness for antimicrobial stewardship?BMC medical education · 2026Article
- Profile and evolution of antimicrobial resistance genes in Staphylococcus aureus whole genomes in Africa revealed by phylogeography and bioinformatics.Scientific reports · 2025Article
- Mitigating inequitable access to appropriate antibiotics in low- and middle-income countries.JAC-antimicrobial resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The departure of pharmaceutical companies from Nigeria - a major source of antimicrobial drug supply in West Africa - increases the risk of an elevated burden of antimicrobial resistance (AMR) in Nigeria and the West Africa subregion. Urgent actions must be taken by relevant actors to address the increased risk of AMR.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.